
News|Articles|September 1, 2003
Aloxi (Palonosetron)
5-HT3 receptor antagonist indicated to prevent delayed CINV
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
3
UC Davis develops new drug for bladder cancer patients
4
Phase 3 trial launches for novel antibody targeting integrin beta-6 in advanced lung cancer
5



















































